logo
Search orAI Icon𝛼SK
ENTITY
Shanghai Henlius Biotech

Shanghai Henlius Biotech (2696 HK)

317
Analysis
Health Care • China
Shanghai Henlius Biotech, Inc develops and produces drugs. The Company develops and produces monoclonal antibody biosimilar drugs, bio betters, novel monoclonal antibodys, and other drugs. Shanghai Henlius Biotech throughout China.
more
Exchange Announcement • 12 Dec 2025 16:46

Voluntary Announcement - New Drug Application (Nda) For Hansizhuang (Serplulimab Injection) In Combination With Chemotherapy For Neo-/ Adjuvant Treatment For Gastric Cancer Has Been Accepted By The National Medical Products Administration (Nmpa) And Has Been Granted Priority Review

Exchange Announcement • 09 Dec 2025 17:14

Voluntary Announcement - Applications For Phase 2/3 Clinical Trials Of Hlx22 (Recombinant Humanised Anti-Her2 Monoclonal Antibody Injection) In Combination With Hlx87 For Injection (Antibody-Drug Conjugate Targeting Her2) For First-Line Treatment Of Her2-Positive Breast Cancer (Bc) And Neoadjuvant Treatment For Her2-Positive Breast Cancer (Bc Neo) Were Approved By The National Medical Products Administration

Exchange Announcement • 07 Dec 2025 18:24

Voluntary Announcement - Inclusion Of Futuoning (Fovinaciclib Citrate Capsules) In The National Reimbursement Drug List

Exchange Announcement • 03 Dec 2025 22:19

Documents On Display - Continuing Connected Transactions - Renewal Of The Sinopharm Distribution Collaboration

Exchange Announcement • 03 Dec 2025 22:05

Proxy Form For The 2025 Fourth Extraordinary General Meeting To Be Held On 31 December 2025 (Or Any Adjournment Thereof)

Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.60.1

x